APP下载

特瑞普利单抗联合AP方案一线治疗手术不可切除的局部晚期非小细胞肺癌研究

2025-08-12丁文金侯建平张琪柳家荣

右江医学 2025年6期
关键词:放化疗单抗肺癌

A study on toripalimab combined with AP regimen as first-line treatment for surgically unresectable locally advanced non-small cell lung cancer

DING Wenjin, HOU Jianping, ZHANG Qi, LIU Jiarong(DepartmentofOncology,General Hospital of PingmeiShenma Group,Pingdingshan 467ooo,Henan,China)

【Abstract】ObjectiveToobservetheeficacyof toripalimabcombinedwithAPregimen inthetreatmentofunresectable locallyadvanced non-smallcellung cancer (LA-NSCLC).MethodsAtotalof 30patients with uresectable LA-NSCLC who received AP regimen chemotherapy + conventional radiotherapy from October 2022 to May 2O23 were enrolled as control group,while 32 patients who received toripalimab + AP regimen chemotherapy + conventional radiotherapy during the same period were included inobservationgroup.The treatment wascontinued for4cycles.After treatment,a2-monthobservation period wasconducted toasess theeficacyAndthen,immunefunctionsbeforeandaftertreatmentadversereactions during the treatment period,and survival statusduring 1-year follow-up were statisticallyanalyzed.ResultsObjectiveresponse rate(ORR)and disease control rate (DCR) in the observation group were 65.63 % and 93.75 % ,respectively,significantly higher than those in the control group( 40.00% and 70.00% )( Plt;0.05 ).After 4 cycles of treatment,the levelsof CD3 + , (2号 CD4+ ,and the CD4 A+ /CD8 + ratio decreased compared to those before treatment in both groups. However, these indicators werehigherin the observation group than in the control group( ).There wasno statisticallysignificant difference in the incidence of adverse reactions during the treatment period between the two groups ( Pgt;0.05 ). Median progression-free survival (PFS)and overall survival (OS)were longer in the observation group than in the control group ( Plt;0.05 ). 1-year survivalratewasslightlyhigherintheobservationgroupthaninthecontrol group,butdiferenceinsurvivalratesbetweenthe two groups was not statistically significant ( Pgt;0. 05 ).ConclusionToripalimab combined with AP regimen has a good overall therapeutic efectonunresectable LA-NSCLC,which can allviate immune suppresioncaused bysynchronous radiotherapyandchemotherapy.Althoughtheshort-termoverallsurvivalrateofpatients has not significantly improved,thesurvival timeis prolonged and the safety is good.

【Keywords】non-smallcellung carcinoma (NSCLC);locally advanced stage;AP regimen;toripalimab;immune suppression;survival period

肺癌是指起源于肺、气管及支气管黏膜上皮的恶性肿瘤。全球癌症调查显示,截至2020年,肺癌死亡人数已超过180万[1]。非小细胞肺癌(non-small celllungcarcinoma,NSCLC)占所有肺癌病例的 80% ~85% ,是肺癌的常见分型。多数患者就诊时已发生局部扩散或转移,约有 27.6% 的NSCLC患者属于不可切除的局部晚期NSCLC(locallyadvanced NSCLC,LA-NSCLC)[2]。LA-NSCLC 是一种高度异质性疾病,常伴有较高的肿瘤负荷和复杂的临床特征。对于未伴有驱动基因突变的不可切除LA-NSCLC患者,临床多选择同步放化疗。LA-NSCLC初始治疗的标准一线化疗方案为含铂双药,其中AP方案(培美曲塞 + 顺铂)作为常用化疗方案,虽可实现精准治疗,但患者的5年生存率仍较低,仅为 15%~25% ,且多数患者容易在1年内复发并对化疗产生耐药[3]

2022年,国家药品监督管理局正式批准将化疗与特瑞普利单抗联合疗法用于局部晚期非鳞状NSCLC的一线治疗。特瑞普利单抗是我国自主研发的程序性死亡蛋白-1(programmed death protein-1,PD-1)抑制剂,通过阻断程序性死亡配体1(pro-grammedcelldeath1ligand1,PD-L1)/PD-1通路,可破坏肿瘤免疫耐受性,刺激淋巴细胞发挥抗肿瘤活性,从而实现持久的抗肿瘤效应[4]。魏小丽等[5]的研究证实,特瑞普利单抗在治疗难治性晚期恶性实体瘤方面表现出良好的药物耐受性和抗肿瘤活性。因此,将AP方案与特瑞普利单抗联合用于不可切除的LA-NSCLC治疗可能带来显著获益,但相关研究仍较为有限。鉴于此,本研究将重点分析特瑞普利单抗联合AP方案治疗不可切除的LA-NSCLC的效果。

1资料与方法

1.1一般资料收集2022年10月—2023年5月期间于本院接受AP方案化疗联合常规放疗的30例不可切除的LA-NSCLC患者资料,纳入对照组;……

登录APP查看全文

猜你喜欢

放化疗单抗肺癌
放疗有误区,千万别中招
卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价
激励式结合预警式护理干预对结直肠癌放化疗患者疲乏程度、自我感受负担的影响
卡瑞利珠单抗联合同步放化疗治疗中晚期食管鳞癌的效果
抗体药物治疗复发/难治性弥漫性大B细胞淋巴瘤的研究进展
非霍奇金淋巴瘤患者MS4A1基因多态性与利妥昔单抗血药浓度及疗效的相关性研究
没有症状就等于生殖健康吗
免疫治疗:肺癌的“革命性疗法”
中医防治肺癌术后并发症
对比增强磁敏感加权成像对肺癌脑转移瘤检出的研究